Cargando…

Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis

BACKGROUND: The precise etiology of knee osteoarthritis (KOA) pain remains highly controversial and there is no known effective treatment. Due to the known and suggested effects of neuropeptide Y (NPY) on pain, we have sought to investigate the relationship between the concentration of NPY in synovi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Zhang, Li, Pan, Haobo, Peng, Songlin, Lv, Minmin, Lu, William Weijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195915/
https://www.ncbi.nlm.nih.gov/pubmed/25262001
http://dx.doi.org/10.1186/1471-2474-15-319
_version_ 1782339383423139840
author Wang, Lei
Zhang, Li
Pan, Haobo
Peng, Songlin
Lv, Minmin
Lu, William Weijia
author_facet Wang, Lei
Zhang, Li
Pan, Haobo
Peng, Songlin
Lv, Minmin
Lu, William Weijia
author_sort Wang, Lei
collection PubMed
description BACKGROUND: The precise etiology of knee osteoarthritis (KOA) pain remains highly controversial and there is no known effective treatment. Due to the known and suggested effects of neuropeptide Y (NPY) on pain, we have sought to investigate the relationship between the concentration of NPY in synovial fluid of knee, pain of KOA, and structural severity of KOA. METHODS: One hundred KOA patients and twenty healthy participants (control group) were recruited. The pain and the radiographic grade of KOA were assessed separately by Hideo Watanabe’s pain score and Tomihisa Koshino’s scoring system. Synovial fluid of knee from all participants was collected with arthrocentesis. Radioimmunoassay was used to examine the concentration of NPY in synovial fluid of knee. RESULTS: Concentrations of NPY in synovial fluid were significantly higher in KOA patients (124.7 ± 33.4 pg/mL) compared with controls (64.8 ± 26.3 pg/mL) (p = 0.0297). According to Hideo Watanabe’s pain score, 100 KOA patients were divided into 5 subgroups: no pain (n = 12), mild pain (n = 25), moderate pain (n = 37), strong pain (n = 19) and severe pain (n = 7). Within the KOA group, significantly higher concentrations of NPY were found in each subgroup as pain intensified (no pain 81.4 ± 11.7 pg/mL, mild pain 99.1 ± 23.2 pg/mL, moderate pain 119.9 ± 31.5 pg/mL, strong pain 171.2 ± 37.3 pg/mL and severe pain 197.3 ± 41.9 pg/mL). Meanwhile, according to Tomihisa Koshino’s scoring system, 100 KOA patients were divided into 3 subgroups: early stage (n = 30), middle stage (n = 53), advanced stage (n = 17). Concentrations of NPY in middle and advanced stage groups of KOA patients were significant higher than early stage group of KOA patients (early stage 96.4 ± 27.1 pg/mL, middle stage 153.3 ± 16.9 pg/mL, advanced stage 149.5 ± 36.7 pg/mL) (p = 0.0163, p = 0.0352). Concentrations of NPY in advanced stage group of KOA patients has no significant difference compare with middle stage group of KOA patients (p = 0. 2175). CONCLUSIONS: This study demonstrated the presence and variation of concentrations of NPY in the KOA joint fluid, suggesting a role for NPY as a putative regulator of pain transmission and perception in KOA pain. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2474-15-319) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4195915
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41959152014-10-15 Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis Wang, Lei Zhang, Li Pan, Haobo Peng, Songlin Lv, Minmin Lu, William Weijia BMC Musculoskelet Disord Research Article BACKGROUND: The precise etiology of knee osteoarthritis (KOA) pain remains highly controversial and there is no known effective treatment. Due to the known and suggested effects of neuropeptide Y (NPY) on pain, we have sought to investigate the relationship between the concentration of NPY in synovial fluid of knee, pain of KOA, and structural severity of KOA. METHODS: One hundred KOA patients and twenty healthy participants (control group) were recruited. The pain and the radiographic grade of KOA were assessed separately by Hideo Watanabe’s pain score and Tomihisa Koshino’s scoring system. Synovial fluid of knee from all participants was collected with arthrocentesis. Radioimmunoassay was used to examine the concentration of NPY in synovial fluid of knee. RESULTS: Concentrations of NPY in synovial fluid were significantly higher in KOA patients (124.7 ± 33.4 pg/mL) compared with controls (64.8 ± 26.3 pg/mL) (p = 0.0297). According to Hideo Watanabe’s pain score, 100 KOA patients were divided into 5 subgroups: no pain (n = 12), mild pain (n = 25), moderate pain (n = 37), strong pain (n = 19) and severe pain (n = 7). Within the KOA group, significantly higher concentrations of NPY were found in each subgroup as pain intensified (no pain 81.4 ± 11.7 pg/mL, mild pain 99.1 ± 23.2 pg/mL, moderate pain 119.9 ± 31.5 pg/mL, strong pain 171.2 ± 37.3 pg/mL and severe pain 197.3 ± 41.9 pg/mL). Meanwhile, according to Tomihisa Koshino’s scoring system, 100 KOA patients were divided into 3 subgroups: early stage (n = 30), middle stage (n = 53), advanced stage (n = 17). Concentrations of NPY in middle and advanced stage groups of KOA patients were significant higher than early stage group of KOA patients (early stage 96.4 ± 27.1 pg/mL, middle stage 153.3 ± 16.9 pg/mL, advanced stage 149.5 ± 36.7 pg/mL) (p = 0.0163, p = 0.0352). Concentrations of NPY in advanced stage group of KOA patients has no significant difference compare with middle stage group of KOA patients (p = 0. 2175). CONCLUSIONS: This study demonstrated the presence and variation of concentrations of NPY in the KOA joint fluid, suggesting a role for NPY as a putative regulator of pain transmission and perception in KOA pain. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2474-15-319) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-27 /pmc/articles/PMC4195915/ /pubmed/25262001 http://dx.doi.org/10.1186/1471-2474-15-319 Text en © Wang et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Lei
Zhang, Li
Pan, Haobo
Peng, Songlin
Lv, Minmin
Lu, William Weijia
Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
title Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
title_full Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
title_fullStr Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
title_full_unstemmed Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
title_short Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
title_sort levels of neuropeptide y in synovial fluid relate to pain in patients with knee osteoarthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195915/
https://www.ncbi.nlm.nih.gov/pubmed/25262001
http://dx.doi.org/10.1186/1471-2474-15-319
work_keys_str_mv AT wanglei levelsofneuropeptideyinsynovialfluidrelatetopaininpatientswithkneeosteoarthritis
AT zhangli levelsofneuropeptideyinsynovialfluidrelatetopaininpatientswithkneeosteoarthritis
AT panhaobo levelsofneuropeptideyinsynovialfluidrelatetopaininpatientswithkneeosteoarthritis
AT pengsonglin levelsofneuropeptideyinsynovialfluidrelatetopaininpatientswithkneeosteoarthritis
AT lvminmin levelsofneuropeptideyinsynovialfluidrelatetopaininpatientswithkneeosteoarthritis
AT luwilliamweijia levelsofneuropeptideyinsynovialfluidrelatetopaininpatientswithkneeosteoarthritis